title: Ghrelin and Helicobacter pylori infection.
abstract: Ghrelin is primarily secreted from the stomach and has been implicated in the coordination of eating behavior and weight regulation. Ghrelin also plays an essential role in the mechanism of gastric mucosal defense. Thus, it is important to clarify which diseases primarily influence changes in plasma ghrelin concentrations. Helicobacter pylori (H pylori) infection is involved in the pathogenesis of gastritis, gastric and duodenal ulcer, gastric carcinoma, and mucosa-associated lymphoid tissue lymphoma. H pylori eradication is related to body weight change. Compared, H pylori infected and negative subjects with normal body mass index, plasma ghrelin concentration, gastric ghrelin mRNA, and the number of ghrelin producing cells in gastric mucosa are significantly lower in H pylori infected subjects than in H pylori-negative controls. Plasma ghrelin concentration decreases with the progression of gastric atrophy. Impaired gastric ghrelin production in association with atrophic gastritis induced by H pylori infection accounts for the decrease in plasma ghrelin concentration. However, the ratio of plasma acylated ghrelin to total ghrelin levels is higher in patients with chronic atrophic gastritis than in healthy subjects. This may result from the compensatory increase in plasma active ghrelin concentration in response to gastric atrophy. After H pylori eradication, gastric preproghrelin mRNA expression is increased nearly 4-fold in most cases. However, changes in plasma ghrelin concentrations before and after H pylori cure are not associated with the gastric ghrelin production. Plasma ghrelin changes are inversely correlated with both body weight change and initial plasma ghrelin levels.
authors.affiliation: Department of Internal Medicine, Division of Gastroenterology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. osawa@jichi.ac.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Osawa
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001284:Atrophy; D015992:Body Mass Index; D002908:Chronic Disease; D004734:Energy Metabolism; D005753:Gastric Mucosa / Q000378:metabolism* / Q000382:microbiology; D005756:Gastritis / Q000378:metabolism / Q000382:microbiology; D054439:Ghrelin / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D012333:RNA, Messenger / Q000378:metabolism; D013270:Stomach / Q000382:microbiology / Q000473:pathology; D015430:Weight Gain
chemical_list: D000900:Anti-Bacterial Agents; D054439:Ghrelin; D012333:RNA, Messenger; C422650:ghrelin, des-n-octanoyl